Michael Hayden

(Dr. Michael Hayden M.D., Ph.D.)

Currently holds positions in Aurinia Pharmaceuticals Inc, Ionis Pharmaceuticals Inc and Xenon Pharmaceuticals Inc

Positions

Position Company Period
Director Aurinia Pharmaceuticals Inc Feb. 22, 2018 -
Director Ionis Pharmaceuticals Inc Sept. 24, 2018 -
Independent Director Xenon Pharmaceuticals Inc Jan. 1, 1996 -
President - Global Research and Development, Chief Scientific Officer Teva Pharmaceutical Industries Ltd May 8, 2012 - Dec. 31, 2017
Michael Hayden's trades of Ionis Pharmaceuticals Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2024-12-26 2024-12-23
B Purchase
2,500 +7.6%
36.23
USD 90,583 		2,500 +7.6% 36.23 USD 90,583
2024-12-26 2024-12-23
B Purchase
2,500 +8.3%
36.20
USD 90,496 		2,500 +8.3% 36.20 USD 90,496
2023-09-26 2023-09-22
B Purchase
20,000 +1.5%
4.91
USD 98,200 		20,000 +1.5% 4.91 USD 98,200
2023-08-09 2023-08-08
B Purchase
30,000 +2.4%
5.90
USD 177,000 		30,000 +2.4% 5.90 USD 177,000
2023-03-30 2023-03-28
US 89Bio Inc (ETNB)
B Purchase
61,538 +inf%
16.15
USD 993,839 		61,538 +inf% 16.15 USD 993,839
2023-03-30 2022-04-25
US 89Bio Inc (ETNB)
B Purchase
10,000 +10.6%
2.67
USD 26,700 		10,000 +10.6% 2.67 USD 26,700
2023-03-30 2022-04-07
US 89Bio Inc (ETNB)
B Purchase
10,000 +11.9%
3.48
USD 34,750 		10,000 +11.9% 3.48 USD 34,750
2023-03-30 2022-03-30
US 89Bio Inc (ETNB)
B Purchase
6,250 +8.0%
3.62
USD 22,625 		6,250 +8.0% 3.62 USD 22,625
2021-06-22 2021-06-22
S Sale
100,000 -9.1%
25.50
USD 2,550,000 		100,000 -9.1% 25.50 USD 2,550,000
2020-12-17 2020-12-15
B Purchase
73,665 +165.2%
20.00
USD 1,473,300 		73,665 +165.2% 20.00 USD 1,473,300
// ... existing code ... // ... rest of the file ...